- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925038
Electronic Communication Augmented Mental Health Care
The Use of Electronic Communications-based Automated Technologies to Augment Traditional Mental Health Care
Mood and anxiety disorders are the most common mental health conditions in the United States, and are associated with significant morbidity, mortality and overall impairment in functioning. These conditions often have an onset in adolescence and can be especially problematic during this time-period because it can impede normal development and attainment of important milestones. While there are evidence-based treatments for these disorders, these disorders often go untreated or under-treated with negative outcomes, particularly suicide in the case of mood disorders. Electronic communication via text messages and social media are ubiquitous and are often the predominant form of communication in adolescents and young adults. A growing body of research suggests that - at the individual level - electronic communication, including social media, activity can reflect the underlying course of mood and anxiety disorders and reveal associated risks for worsening course and negative outcomes such as suicide.
In this pilot study, the investigators propose to develop and evaluate a dashboard for mental health therapists to augment the care of patients with mood/anxiety disorders.
Study Overview
Status
Intervention / Treatment
Detailed Description
Mood and anxiety disorders are among the most common mental health disorder in the United States, and these disorders are associated with significant morbidity, mortality and overall impairment in functioning. These disorders often have an onset in adolescence, and suicide is now the second leading cause of death among 15-29 year-olds. Furthermore, adolescent mood and anxiety disorders are increasing, with lifetime prevalence of major depressive disorder for adolescents now estimated at 11%. For adolescents and young adults, untreated mood and anxiety disorders can impede normal development and attainment of important milestones (i.e., high school or college graduation, transition to employment), in addition to greatly increasing the risk of suicide. While there are evidence-based treatments for these disorders, 40% of depressed adolescent patients, for example, do not have a substantial response to initial treatment and only a third experience remission of symptoms. Consequently, there is an urgent need to improve upon current treatments and develop novel approaches to care of depression, as well as other mood and anxiety disorders, in adolescents, young adults, and adults in general.
Electronic communication is ubiquitous. Given this, it has been hypothesized that monitoring electronic communication, including social media, activity in partnership with patients as part of routine clinical care has the potential to prevent negative outcomes of mood and anxiety disorders and greatly improve care of these conditions. At the individual level, electronic communication activity can reflect the underlying course of these disorders and reveal associated risks for worsening course and negative outcomes such as suicide. Automated technologies (e.g., natural language processing systems) may assist therapists in assessing these conditions and risks, by identifying aspects of language use or other key behavior patterns, such as number of friends or time of electronic communication activity, that correlate with an individual's mental health status. At the population level, analysis of aggregated electronic communications data can illuminate important mental health trends across a range of disorders (e.g., depression, bipolar disorder, anxiety, eating disorders). In this pilot study, the investigators propose to develop and evaluate a dashboard for mental health therapists in alliance with patients to augment the care of patients with mood/anxiety disorders and to improve clinical outcomes.
Of note, changes to primary, secondary, and other pre-specified outcomes were made prior to intervention implementation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Leslie Miller, MD
- Phone Number: 410 550 9014
- Email: lmille84@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ages 12-100 years
- With any diagnosis of a mood or anxiety disorder
- Already established and receiving care in community psychiatry at the Johns Hopkins Bayview Medical Center or at Johns Hopkins Hospital or Kennedy Krieger Institute.
Exclusion Criteria:
- Non-English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment as Usual
Participants will receive psychotherapy (treatment as usual).
|
Participants will receive psychotherapy as treatment as usual.
|
Experimental: Augmented Care
Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
|
Participants will receive psychotherapy as treatment as usual.
A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Depressive symptoms as assessed by the Patient Health Questionnaire 9
Time Frame: Baseline, then weekly for up to 2 years
|
Items are rated on a 4-point scale (0=not at all, 3=Nearly every day).
A total score range of 0-27 is computed based on patient self-reports on the nine items.
Depression severity is interpreted based on the total score (1-4= Minimal depression; 20-27= Severe depression).
|
Baseline, then weekly for up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Session Experience Scale
Time Frame: First visit, then every visit for up to 2 years
|
Items are rated on a 10-point scale (0=Worst; 10=Best).
|
First visit, then every visit for up to 2 years
|
Change in measurement based outcomes as measured by the McLean Treatment Tracking Survey
Time Frame: First visit, then every visit for up to 2 years
|
Items collect collateral information obtained and treatment decisions.
|
First visit, then every visit for up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in therapist-patient therapeutic relationship as assessed by the Working Alliance Inventory
Time Frame: Baseline, then every 3 months for up to 2 years
|
Items are rated on a 5-point scale (1=Seldom; 5=Always).
|
Baseline, then every 3 months for up to 2 years
|
Change in Anxiety symptoms as assessed by the General Anxiety Disorder 7
Time Frame: Baseline, then weekly for up to 2 years
|
Items are rated on a 4-point scale (0=not at all; 3=Nearly every day).
A total score range (0-21) is computed based on patient self-reports on the seven items.
Anxiety severity is interpreted based on the total score (1-5 = Minimal anxiety; 15-21= Severe anxiety).
|
Baseline, then weekly for up to 2 years
|
Change in Suicide symptoms as assessed by the Columbia-Suicide Severity Rating Scale
Time Frame: Baseline, then weekly for up to 2 years
|
Items are dichotomous (yes or no)
|
Baseline, then weekly for up to 2 years
|
Change in self-reported quality of life as assessed by Short Form 36 Mental Health Component (SF-36 MHC)
Time Frame: Baseline, then every 3 months for up to 2 years
|
Items are dichotomous (yes or no), and rated on 5-point (1= Not at all; 5= Extremely) and 6-point (1=All of the time; 6= None of the time)scales
|
Baseline, then every 3 months for up to 2 years
|
Change in satisfaction with services as assessed by Client Satisfaction Questionnaire
Time Frame: Baseline, then every 3 months for up to 2 years
|
Items are rated on 4-point scale (e.g., 1= Poor; 4= Excellent)
|
Baseline, then every 3 months for up to 2 years
|
Change in therapist satisfaction with electronic communication data discussion as assessed by Electronic Data and Mental Health Satisfaction Questionnaire
Time Frame: First visit, then every visit for up to 2 years
|
Items are rated on a 7-point scale (1= Not at all; 7= A great deal) including additional items that inquire about effects of electronic communication data discussion
|
First visit, then every visit for up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Margaret Chisolm, Johns Hopkins University
Publications and helpful links
General Publications
- Avenevoli S, Swendsen J, He JP, Burstein M, Merikangas KR. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry. 2015 Jan;54(1):37-44.e2. doi: 10.1016/j.jaac.2014.10.010. Epub 2014 Oct 29.
- Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry. 2003 Jul;60(7):709-17. doi: 10.1001/archpsyc.60.7.709.
- Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27;299(8):901-913. doi: 10.1001/jama.299.8.901. Erratum In: JAMA. 2019 Nov 5;322(17):1718.
- McLaughlin KA. The public health impact of major depression: a call for interdisciplinary prevention efforts. Prev Sci. 2011 Dec;12(4):361-71. doi: 10.1007/s11121-011-0231-8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00184638
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
Clinical Trials on Treatment as Usual
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
McMaster UniversityNot yet recruiting
-
Gaia AGRecruitingType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted
-
King's College LondonUnknown
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain
-
Kuopio University HospitalUniversity of Oslo; University of Eastern Finland; City of KuopioRecruiting